Hi-Tech Pharmacal Receives Final Approval for Fluticasone Propionate Nasal Spray, 50mcg

On January 16, 2008 Hi-Tech Pharmacal, Inc. announced that the US Food and Drug Administration (FDA) granted final approval to the Company's Abbreviated New Drug Application (ANDA) for fluticasone propionate nasal spray, 50mcg. Hi-Tech's fluticasone propionate nasal spray is the AB-rated generic equivalent of GlaxoSmithKline's Flonase(R)*, which is used in the management of the nasal symptoms of seasonal and perennial allergic and non-allergic rhinitis. Sales of branded and generic fluticasone propionate nasal spray, 50mcg was over $700 million for the 12 months ended June 2007 according to IMS sales data. Hi-Tech's fluticasone propionate nasal spray, 50mcg is available for immediate shipment.

David Seltzer, President and CEO of Hi-Tech Pharmacal said, "We are very excited about the approval of fluticasone propionate nasal spray. Given the large size of the market and the limited number of competitors, we are optimistic about the contribution that this product will make to the Company's sales and profits."

*Hi-Tech Pharmacal is not affiliated with the owner of the trademark Flonase(R).